Factors related to mortality in patients with chronic obstructive pulmonary disease in Colombian population
Abstract
Introduction. Data in low- and middle-income countries on mortality and its related risk factors in patients with chronic obstructive pulmonary disease are limited.
Objective. To identify the incidence of death and its relationship with variables in a Colombian population during 12 months of follow-up.
Materials and methods. We carried out a retrospective study in subjects diagnosed with chronic obstructive pulmonary disease in a third-level hospital in Colombia. Odds ratios were calculated using multivariable logistic regression analysis with the outcome variable “mortality at 12 months”.
Results. We included 524 patients, 18.1% (95 / 524) died. The average age was 69.7 (SD = 8.92), and 59.2% (310 / 524) were women. The variables associated with mortality were age (OR = 6.54; 95% CI = 3.65-11.36; p < 0.001), years of exposure to wood smoke (OR = 4.59; 95% CI = 1.64-2.82; p = 0.002), chronic heart failure (OR = 1.81; 95% CI = 1.13-2.91; p = 0.014), cerebrovascular disease (OR = 3.35; 95% CI = 1.04-10.75; p = 0.032), and chronic kidney disease (OR = 6.96; 95% CI = 1.15-41.67; p=0.015). When adjusting the variables in the multivariate analysis, only an association was found for sex (OR = 1.55; 95% CI = 0.95-2.54; p = 0.008) and age (OR = 5.94; 95% CI = 3.3-10.69; p < 0.001).
Conclusion. Age, years of exposure to wood smoke, chronic heart failure, and cerebrovascular and chronic kidney disease were the clinical variables associated with
a fatal outcome. However, age and sex were the only variables related to mortality when adjusted for confounding factors.
Downloads
References
Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61:2300239. https://doi.org/10.1183/13993003.00239-2023
Global Burden of Disease - GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8:585-96. https://doi.org/10.1016/S2213-2600(20)30105-3
Yang W, Li F, Li C, Meng J, Wang Y. Focus on early COPD: Definition and early lung development. Int J Chron Obstruct Pulmon Dis. 2021;16:3217-28. https://doi.org/10.2147/COPD.S338359
Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Høines K, Stratelis G, et al. COPD - Do the right thing. BMC Fam Pract. 2021;22:244. https://doi.org/10.1186/s12875-021-01583-w
Mei F, Dalmartello M, Bonifazi M, Bertuccio P, Levi F, Boffetta P, et al. Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019. Respirology. 2022;27:941-50. https://doi.org/10.1111/resp.14328
Marshall DC, Al Omari O, Goodall R, Shalhoub J, Adcock IM, Chung KF, et al. Trends in prevalence, mortality, and disability-adjusted life-years relating to chronic obstructive pulmonary disease in Europe: An observational study of the global burden of disease database, 2001-2019. BMC Pulm Med. 2022;22:289. https://doi.org/10.1186/s12890-022-02074-z
Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133:343-9. https://doi.org/10.1378/chest.07-1361
Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis. Lancet Respir Med. 2022;10:447-58. https://doi.org/10.1016/S2213-2600(21)00511-7
Ortiz-Quintero B, Martínez-Espinosa I, Pérez-Padilla R. Mechanisms of lung damage and development of COPD due to household biomass-smoke exposure: Inflammation, oxidative stress, microRNAs, and gene polymorphisms. Cells. 2022;12:67. https://doi.org/10.3390/cells12010067
Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173:ITC17-32. https://doi.org/10.7326/AITC202008040
Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger JB, et al. Realworld retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28:33. https://doi.org/10.1038/s41533-018-0101-y
Ellingsen J, Johansson G, Larsson K, Lisspers K, Malinovschi A, Ställberg B, et al. Impact of comorbidities and commonly used drugs on mortality in COPD - Real-world data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235-45. https://doi.org/10.2147/COPD.S231296
Giezeman M, Sundh J, Athlin Å, Lisspers K, Ställberg B, Janson C, et al. Comorbid heart disease in patients with COPD is associated with increased hospitalization and mortality - A 15-year follow-up. Int J Chron Obstruct Pulmon Dis. 2023;18:11-21. https://doi.org/10.2147/COPD.S378979
Jones PW, Mullerova H, Agusti A, Decramer M, Adamek L, Raillard A, et al. Cardiovascular disease does not predict exacerbation rate or mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197:400-3. https://doi.org/10.1164/rccm.201706-1066LE
Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022 ;399:2227-42. https://doi.org/10.1016/S0140-6736(22)00470-6
Grosbois JM, Détrée A, Pierache A, Bautin N, Pérez T, Wallaert B, et al. Impact of cardiovascular and metabolic comorbidities on long-term outcomes of home-based pulmonary rehabilitation in COPD. Int J Chron Obstruct Pulmon Dis. 2023;18:155-67. https://doi.org/10.2147/COPD.S381744
Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014:CD009285. https://doi.org/10.1002/14651858.CD009285.pub3
Cuthbert JJ, Pellicori P, Clark AL. Optimal management of heart failure and chronic obstructive pulmonary disease: Clinical challenges. Int J Gen Med. 2022;15:7961-75. https://doi.org/10.2147/IJGM.S295467
Gomes F, Cheng SL. Pathophysiology, therapeutic targets, and future therapeutic alternatives in COPD: Focus on the importance of the cholinergic system. Biomolecules. 2023;13:476. https://doi.org/10.3390/biom13030476
James BD, Jones AV, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: Is exercise the answer? Chron Respir Dis. 2018;15:173-81. https://doi.org/10.1177/1479972317736294
DeLapp DA, Glick C, Furmanek S, Ramirez JA, Cavallazzi R. Patients with obesity have better long-term outcomes after hospitalization for COPD exacerbation. Chronic Obstr Pulm Dis. 2020;17:373-7. https://doi.org/10.1080/15412555.2020.1781805
Some similar items:
- Luis Eduardo Echeverría, Clara Saldarriaga, Sebastián Campbell-Quintero, Lisbeth Natalia Morales-Rodríguez, Juan David López-Ponce de León, Andrés Felipe Buitrago, Erika Martínez-Carreño, Jorge Alberto Sandoval-Luna, Alexis Llamas, Gustavo Adolfo Moreno-Silgado, Julián Vanegas-Eljach, Nelson Eduardo Murillo-Benítez, Ricardo Gómez-Paláu, Alex Arnulfo Rivera-Toquica, Juan Esteban Gómez-Mesa, RECOLFACA research group, Diabetes mellitus in patients with heart failure and effect modification of risk factors for short-term mortality: An observational study from the Registro Colombiano de Falla Cardíaca (RECOLFACA) , Biomedica: Vol. 44 No. Sp. 1 (2024): Enfermedades crónicas no transmisibles
- Liliana Villa, Iván Mauricio Trompa, Fernando Nicolás Montes, Joaquín Guillermo Gómez, Carlos Andrés Restrepo, Analysis of mortality caused by tuberculosis in Medellín, Colombia, 2012 , Biomedica: Vol. 34 No. 3 (2014)
- Álvaro J. Ruiz, Pablo J. Aschner, María Fernanda Puerta, Rafael Alfonso-Cristancho, IDEA Study (International Day for the Evaluation of Abdominal Obesity): Primary care study of the prevalence of abdominal obesity and associated risk factors in Colombia , Biomedica: Vol. 32 No. 4 (2012)
- Mauricio Beltrán, María Cristina Navas, María Patricia Arbeláez, Jorge Donado, Sergio Jaramillo, Fernando De la Hoz, Cecilia Estrada, Lucía del Pilar Cortés, Amalia de Maldonado, Gloria Rey, Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Ligia Inés Moncada, Sandra Milena Rios, Julián Alfredo Fernández, Fabio Rivas, María Luz Sáenz, Pediculosis prevalence and associated risk factors in a nursery school, Bogotá, Colombia , Biomedica: Vol. 28 No. 2 (2008)
- Karen Melissa Ordóñez, Odismar Andrea Hernández, Jorge Alberto Cortés, María José López, Gladys Alfonso, Alejandro Junca, Left-sided infective endocarditis caused by Pseudomonas aeruginosa treated medically , Biomedica: Vol. 30 No. 2 (2010)
- Alicia Norma Alayón, Saudith Ariza, Karen Baena, Lina Lambis, Lina Martínez, Lourdes Benítez, Active search and assessment of cardiovascular risk factors in young adults, Cartagena de Indias, 2007 , Biomedica: Vol. 30 No. 2 (2010)
- María del Pilar Chaves, Julián Alfredo Fernández, Isabel Ospina, Myriam Consuelo López, Ligia Moncada, Patricia Reyes, Giardia duodenalis prevalence and associated risk factors in preschool and school-age children of rural Colombia , Biomedica: Vol. 27 No. 3 (2007)
- Elpidia Poveda, Alexandra Cuartas, Saralicia Guarín, Yibby Forero, Elsa Villarreal, Iron and vitamin A micronutrient status, risk factors for their deficiencies and anthropometric assessment in preschool child from Funza municipality, Colombia , Biomedica: Vol. 27 No. 1 (2007)
- Richard Hoyos, Lisandro Pacheco, Luz Adriana Agudelo, German Zafra, Pedro Blanco, Omar Triana, Seroprevalence of Chagas disease and associated risk factors in a population of Morroa, Sucre , Biomedica: Vol. 27 No. 1esp (2007): Enfermedad de Chagas
Copyright (c) 2024 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
Funding data
-
Universidad de La Sabana
Grant numbers MED-263-2019
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
